EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #04437_C
含重组细胞因子的甲基纤维素培养基用于人细胞的快速造血集落测定
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
MethoCult™Express用于人脐带血（CB）样本的造血集落形成单位（CFU）检测，最低培养期为7天。适用于去除红细胞的脐带血样本，冻存复苏后的全脐带血样本，以及脐带血单个核细胞（CB-MNC）样本。MethoCult™Express对人造血祖细胞的生长和计数进行了优化，所需时间比标准CFU检测的14 -16天短得多。在MethoCult™Express中，在培养7天后即可计数包含至少20个细胞的集落。此时，大多数集落是不成熟的，尚未分化成形态上可区分的集落类型。因此7天时的集落数量主要反映样本中造血祖细胞的总频率，而不区分不同类型的祖细胞。
如果将培养时间延长到14 - 16天，可以计数来自不同祖细胞的集落，包括：红系祖细胞形成的BFU-E集落、粒细胞-巨噬细胞系祖细胞形成的CFU-G、CFU-M、CFU-GM集落、多潜能祖细胞形成的CFU-GEMM集落。
浏览我们关于CFU分析的常见问题解答（FAQs），并探索其作为细胞治疗工作流程中的应用价值。
包含
• 含甲基纤维素的Iscove's MDM
• 胎牛血清
• 牛血清白蛋白
• 细胞因子，包括促红细胞生成素 (EPO)
• 添加物
分类
半固体培养基，专用培养基
细胞类型
造血干/祖细胞
种属
人
应用
细胞培养，克隆筛选，功能学筛选
品牌
MethoCult
研究领域
脐带血库，干细胞生物学，移植研究
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (11)
常见问题
文献 (9)
NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIalpha and DNA-dependent protein kinase. Blood 2011 MAR
Abstract
Adult T-cell leukemia-lymphoma (ATL) is an aggressive disease, incurable by standard chemotherapy. NK314, a new anticancer agent possessing inhibitory activity specific for topoisomerase IIα (Top2α), inhibited the growth of various ATL cell lines (50% inhibitory concentration: 23-70nM) with more potent activity than that of etoposide. In addition to the induction of DNA double-strand breaks by inhibition of Top2α, NK314 induced degradation of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), resulting in impaired DNA double-strand break repair. The contribution of DNA-PK to inhibition of cell growth was affirmed by the following results: NK314 inhibited cell growth of M059J (a DNA-PKcs-deficient cell line) and M059K (a cell line with DNA-PKcs present) with the same potency, whereas etoposide exhibited weak inhibition of cell growth with M059K cells. A DNA-PK specific inhibitor, NU7026, enhanced inhibitory activity of etoposide on M059K as well as on ATL cells. These results suggest that NK314 is a dual inhibitor of Top2α and DNA-PK. Because ATL cells express a high amount of DNA-PKcs, NK314 as a dual molecular targeting anticancer agent is a potential therapeutic tool for treatment of ATL.
Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008 OCT
Abstract
Outcomes of 159 young patients with inherited metabolic disorders (IMDs) undergoing transplantation with partially HLA-mismatched unrelated donor umbilical cord blood were studied to investigate the impact of graft and patient characteristics on engraftment, overall survival (OS), and graft-versus-host disease (GVHD). Patients received myeloablative chemotherapy (busulfan, cyclophosphamide, ATG) and cyclosporine-based GVHD prophylaxis. Infused cell doses were high (7.57 x 10(7)/kg) because of the patients' young age (median, 1.5 years) and small size (median, 12 kg). Median follow-up was 4.2 years (range, 1-11 years). The cumulative incidences of neutrophil and platelet engraftment were 87.1% (95% confidence interval [CI], 81.8%-92.4%) and 71.0% (95% CI, 63.7%-78.3%). A total of 97% achieved high (textgreater 90%) donor chimerism. Serum enzyme normalized in 97% of patients with diseases for which testings exist. Grade III/IV acute GVHD occurred in 10.3% (95% CI, 5.4%-15.2%) of patients. Extensive chronic GVHD occurred in 10.8% (95% CI, 5.7%-15.9%) of patients by 1 year. OS at 1 and 5 years was 71.8% (95% CI, 64.7%-78.9%) and 58.2% (95% CI, 49.7%-66.6%) in all patients and 84.5% (95% CI, 77.0%-92.0%) and 75.7% (95% CI, 66.1%-85.3%) in patients with high (80-100) performance score. In multivariate analysis, favorable factors for OS were high pretransplantation performance status, matched donor/recipient ethnicity, and higher infused colony forming units.
Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment. Bone marrow transplantation 2005 MAY
Abstract
In all, 78 peripheral hematopoietic progenitor cell collections from 52 patients were evaluated using our previously published validated post-thaw assays at the time of collection and following transplantation by assessment of viable CD34(+) cells, and granulocyte-macrophage colony-forming units (CFU-GM) cryopreserved in quality control vials. The median (range) post-thaw recovery of viable CD34(+) cells and CFU-GM was 66.4% (36.1-93.6%) and 63.0% (28.6-85.7%), respectively, which did not show significant correlation with the engraftment of either neutrophils (P=0.136 and 0.417, respectively) or platelets (P=0.88 and 0.126, respectively). However, the reinfused viable CD34(+) cells/kg of patient weight pre- or post-cryopreservation showed significant correlation to engraftment of neutrophils (P=0.0001 and 0.001, respectively) and platelets (P=0.023 and 0.010, respectively), whereas CFU-GM pre- or post-cryopreservation was significantly correlated to neutrophils (P=0.011 and 0.007, respectively) but not to platelets (P=0.112 and 0.100, respectively). The results show that post-cryopreservation assessment of viable CD34(+) cells or CFU-GM is as reliable a predictor of rapid engraftment as that of pre-cryopreservation measures. Therefore, the post-cryopreservation number of viable CD34(+) cells or CFU-GM should be used to eliminate the risks of unforeseen cell loss that could occur during cryopreservation or long-term storage.
更多信息
| 种属 | Human |
|---|---|
| Contains | • Methylcellulose in Iscove's MDM • Fetal bovine serum • Bovine serum albumin • Cytokines, including erythropoietin (EPO) • Supplements |
相关产品
-
HetaSep™新鲜血液样本中去除红细胞并分离有核细胞
-
STEMvision™用于造血集落形成单位（CFU）测定的自动化和标准化集落计数
